efficiency and quality
of project objectives
With a consortium as multidisciplinary as ARDAT, in order to ensure focused and integrated collaborative work across the consortium, we have a detailed strategy for project management, governance, and communication. The project is coordinated by University of Sheffield, managed by Pharmacoidea Ltd., and Pfizer Inc. is responsible for project lead.
Prof. Azzouz, formerly Director of Neurobiology at Oxford BioMedica Ltd, has an extensive record both in academia and in industry and expertise in the management of large research programmes (e.g. ERC Advanced, JPND). Prof. Azzouz has achieved international pre-eminence in the field of gene therapy applications and vector development for neurodegenerative diseases. He is currently leading a rich pipeline of gene therapy projects at various stages of pre-clinical and clinical development. His track record of translational research productivity is characterized by publications in top ranking scientific journals and patents.
Dr. LaRosa is the Head of Scientific Research, in Pfizer’s Rare Disease Research Unit (RDRU). Dr. LaRosa has 30+ years of experience in biopharmaceutical discovery research and development. This work has been focused on Immunology, Rare Disease, and AAV as a drug candidate for several rare diseases. In his current role Dr. LaRosa oversees the R&D strategy, and in particular, the external research and development collaborations for the RDRU. He has over 50 peer-reviewed publications.
As a scientist, Dr. Letoha exploits heparan-sulfate proteoglycans' therapeutic potential and published several publications and patents in the field. As an entrepreneur, Dr. Letoha manages the business and scientific aspects of his company, Pharmacoidea, now serving as a managing entity for ARDAT. Previous participation in R&D projects funded by the Innovative Medicines Initiative proves that Dr. Letoha has hands-on knowledge of managing complex drug discovery projects, as required by ARDAT.